Lenvima for neuroendocrine cancer – pro
Capdevilla reported that lenvatinib showed a promising PFS and OS in a pretreated population with benefits across subgroups. However, there are no guidelines supporting it and more studies need to be done.
Jaume Capdevila et al, Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs). Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 4106-4106.
Capozzi M, De Divitiis C, Ottaiano A, et al. Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res. 2019;11:3847-3860. Published 2019 May 1. doi:10.2147/CMAR.S188316